Our pipeline includes three Core Products: two immunocytokines and one ADCC enhanced mAb. The two immunocytokines, IAP0971 and IAE0972, were developed based on our AICTM platform. The ADCC enhanced mAb, IAH0968, was developed based on our AEATM Platform. The following chart summarizes the development status of our Core Products and other selected product candidates as of the Latest Practicable Date.

Overall Strategy of SunHo R&D Pipeline

SunHo attaches great importance to protect intellectual property, safeguard innovative products, and guarantee future commercial benefits. Through comprehensive consideration of products, technologies, markets, regions, and overall strategies, SunHo forms valuable patent portfolio to protect the R&D achievements effectively. As of the Latest Practicable Date, we owned four issued patents and 102 patent applications, including 49 patent applications in China, one patent application in the U.S., and 52 patent applications under the Patent Cooperation Treaty (“PCT”), relating to certain of our product candidates and technologies.